Context
Nicox is a French-listed international ophthalmic company that develops innovative solutions to help maintain vision and improve ocular health.
Nicox’s main candidate, NCX 470, is set to become a best-in-class in glaucoma treatment by capitalizing on the same dual action as its first-generation VYZULTA treatment, which has been commercialized in the US and Canada, while leveraging the higher efficacy of glaucoma treatment bimatoprost.
Nicox’s second candidate, NCX 4251, could become the first treatment for blepharitis, one of the most common ocular diseases and one that has no approved treatment.
Follow-on Offering proceeds will be mainly used to complete the ongoing NCX 470 Denali clinical trial, complete activities related to the NCX 470 Mont Blanc trial and the Mississippi trial on NCX 4251 (both due to report top-line data in Q4 2021) and initiate pre-clinical activities on its NCX 1728 development candidate.
About Nicox
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating bimatoprost analog for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA in glaucoma, licensed exclusively worldwide to Bausch & Lomb, and ZERVIATE in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.
Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.
Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner to Nicox on its EUR 15 million Follow-on Offering
Bryan, Garnier & Co acted as Joint Global Coordinator and Joint Bookrunner on NICOX’s Follow-on Offering. This is the fourth time that Nicox has engaged Bryan, Garnier & Co’s services for a capital raise, in a relationship that has led to both corporate finance and research coverage.
Nicox raised EUR 15m from select Tier-1 biotech specialists, with one-third of funds raised allocated to US investors. The company’s largest shareholder, HBM Partners, also participated, for 7% of the offering.
This is Bryan, Garnier & Co’s 12th capital raise for a biotech in 2020 and its eighth for a Euronext Paris-listed biotech. It marks another landmark transaction and cements Bryan, Garnier & Co’s leading position in its Healthcare and Equity Capital Markets franchises.
The transaction also confirms Bryan, Garnier & Co’s position as #1 investment bank on Euronext issuances in 2020.
Share